STAT+: Why the JP Morgan conference is important — but not make-or-break

This is the online version of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.

My advice for JPM week: chill

SAN FRANCISCO — The super-sized gathering of the biopharma universe is important, but it’s not going to make or break the year for biotech. Acquisitions, partnerships, and funding agreements will be hatched during meetings here over the next week. That’s a major reason why thousands of industry people descend on the city and put up with overpriced hotel rooms. 

News flash: All of the stuff that makes biotech go vroom also happens during the 51 remaining weeks of the year.

Continue to STAT+ to read the full story…